Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
Deutsches Herzzentrum München and 1. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. dirk@sibbing.net
Dirk
D
Sibbing
Isabell
I
Bernlochner
Adnan
A
Kastrati
Guillaume
G
Paré
John W
JW
Eikelboom
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics / Q000378:metabolism*; D054316:Biomarkers, Pharmacological / Q000378:metabolism*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005820:Genetic Testing / Q000639:trends; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D057285:Precision Medicine; D058925:Receptors, Purinergic P2Y12 / Q000378:metabolism; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome
D054316:Biomarkers, Pharmacological; C548576:P2RY12 protein, human; D010975:Platelet Aggregation Inhibitors; D058925:Receptors, Purinergic P2Y12; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine